Michael Charles A. Booth
Keine laufenden Positionen mehr
Profil
Michael Charles A.
Booth worked as a Research Analyst at Canaccord Adams Ltd.
from 2003 to 2007.
He then served as a Director at Trout International LLC from 2007 to 2011.
Later, he worked as a Senior VP-Communications & Corporate Affairs at Algeta ASA. From 2014 to 2021, he worked at Incyte Corp.
and held the position of Division Vice President-Investor Relations from 2019 to 2021.
Booth holds an undergraduate degree from the University of St. Andrews and a doctorate from the University of Oxford.
Ehemalige bekannte Positionen von Michael Charles A. Booth
| Unternehmen | Position | Ende |
|---|---|---|
| INCYTE CORPORATION | Investor Relations Contact | - |
| Canaccord Adams Ltd. | Analyst-Equity | 09.08.2007 |
| ALGETA ASA | Investor Relations Contact | - |
| Trout International LLC | Corporate Officer/Principal | - |
Ausbildung von Michael Charles A. Booth
| University of Oxford | Doctorate Degree |
| University of St. Andrews | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| Canaccord Adams Ltd. | Finance |
| Trout International LLC | |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
